Free Trial

MDxHealth Q1 2023 Earnings Report

MDxHealth logo
$2.26 +0.10 (+4.63%)
(As of 12/20/2024 05:16 PM ET)

MDxHealth EPS Results

Actual EPS
-$0.50
Consensus EPS
-$4.00
Beat/Miss
Beat by +$3.50
One Year Ago EPS
N/A

MDxHealth Revenue Results

Actual Revenue
$14.70 million
Expected Revenue
$13.78 million
Beat/Miss
Beat by +$920.00 thousand
YoY Revenue Growth
N/A

MDxHealth Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

MDxHealth Earnings Headlines

Reviewing BioNexus Gene Lab (NASDAQ:BGLC) & MDxHealth (NASDAQ:MDXH)
Could This Tiny Device Help You Make an Extra $30k a Year?
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
BTIG Sticks to Its Buy Rating for MDxHealth (MDXH)
MDxHealth price target lowered to $6 from $8 at BTIG
See More MDxHealth Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MDxHealth? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MDxHealth and other key companies, straight to your email.

About MDxHealth

MDxHealth (NASDAQ:MDXH), a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

View MDxHealth Profile

More Earnings Resources from MarketBeat

Upcoming Earnings